YUTREPIA (Treprostinil Sodium) Patent Expiration, LOE Window & CMS Spending

YUTREPIA (Treprostinil Sodium) by Liquidia Technologies: FDA Orange Book core substance LOE 2037-05-05, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $6,090 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorLiquidia Technologies
FDA Application & PathwayN213005 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2037-05-05
Last Listed Patent or Exclusivity Date2037-05-05
Orange Book Patents (*PED Extensions)24 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($6,090 intro WAC)